Stephens Raises Health Catalyst (NASDAQ:HCAT) Price Target to $9.00

Health Catalyst (NASDAQ:HCAT) had its price target lifted by analysts at Stephens from $7.00 to $9.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Stephens’ target price suggests a potential upside of 17.65% from the company’s previous close.

A number of other equities analysts have also commented on the stock. Evercore ISI boosted their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Citigroup increased their price target on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a report on Wednesday. Piper Sandler lowered their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Finally, Royal Bank of Canada lifted their price target on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Health Catalyst currently has an average rating of “Moderate Buy” and an average target price of $11.71.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $7.65 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41. The company has a market capitalization of $465.50 million, a price-to-earnings ratio of -6.08 and a beta of 1.32. The business has a 50-day moving average of $8.15 and a 200-day moving average of $7.21.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period last year, the business earned ($0.22) EPS. The firm’s revenue was up 3.5% compared to the same quarter last year. On average, equities analysts anticipate that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of the stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at approximately $1,062,018.64. This represents a 5.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,068 shares of company stock worth $257,555 over the last ninety days. 2.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors have recently made changes to their positions in the stock. Inspire Investing LLC acquired a new position in Health Catalyst during the 1st quarter valued at approximately $355,000. Acadian Asset Management LLC boosted its holdings in shares of Health Catalyst by 38.3% during the first quarter. Acadian Asset Management LLC now owns 724,560 shares of the company’s stock valued at $5,453,000 after acquiring an additional 200,494 shares during the period. EntryPoint Capital LLC bought a new position in shares of Health Catalyst during the first quarter worth about $98,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Health Catalyst by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock worth $375,000 after acquiring an additional 2,831 shares during the period. Finally, Kennedy Capital Management LLC bought a new stake in Health Catalyst in the 1st quarter valued at about $8,780,000. 85.00% of the stock is owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.